Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C P Moiola

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Experimental Neurology|March 24, 2009
Partial inhibition of proteasome activity enhances remyelination after cuprizone-induced demyelinationV Millet, C P Moiola, J M Pasquini, et al.
Prostate Cancer and Prostatic Diseases|May 15, 2013
BRCA1 and p53 regulate critical prostate cancer pathwaysP De Luca, C P Moiola, F Zalazar, et al.
Gynecologic Oncology|September 12, 2022
The amount of preoperative endometrial tissue surface in relation to final endometrial cancer classificationS W Vrede, A M C Hulsman, C Reijnen, et al.
Gynecologic Oncology|April 16, 2021
Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancerS W Vrede, W J van Weelden, N C M Visser, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Experimental Neurology|March 24, 2009
Partial inhibition of proteasome activity enhances remyelination after cuprizone-induced demyelinationV Millet, C P Moiola, J M Pasquini, et al.
Prostate Cancer and Prostatic Diseases|May 15, 2013
BRCA1 and p53 regulate critical prostate cancer pathwaysP De Luca, C P Moiola, F Zalazar, et al.
Gynecologic Oncology|September 12, 2022
The amount of preoperative endometrial tissue surface in relation to final endometrial cancer classificationS W Vrede, A M C Hulsman, C Reijnen, et al.
Gynecologic Oncology|April 16, 2021
Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancerS W Vrede, W J van Weelden, N C M Visser, et al.
Pageof 1